Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Pyrosequencing and University of Geneva Add To Down Syndrome Diagnostics Deal

NEW YORK, May 7-The Swedish firm Pyrosequencing and the University of Geneva today said that they would work together to develop new prenatal screens for a range of chromosomal diseases.


The research project expands upon a collaboration launched last August to develop a diagnostic for Down Syndrome. The test has been created and is now being clinically evaluated.


This expanded partnership will develop genetic tests for other types of chromosomal trisomy, including trisomy 18 (Edward's Syndrome) and trisomy 13 (Patau's Syndrome). These syndromes, while less common than Down syndrome, cause profound mental retardation and generally fatal health problems.


The collaboration is structured so that Pyrosequencing's Molecular Diagnostics business unit sponsors research at the Swiss university to carry out the gene analysis. Financial details were not revealed.


Pyrosequencing is a publicly held company based in Uppsala, Sweden.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.